Galanin is a 30 amino acid non-amidated peptide in humans and identified in 14 other species as a 29 amino acid C-terminally amidated peptide. Galanin is widely distributed in both the central and peripheral nervous systems and the endocrine system. Galanin's wide spectrum of biological activities makes the galaninergic system a promising target for possible therapeutic intervention in pain signaling, cognitive decline, neuroprotection, feeding behavior and controlling insulin release. Galanin affects the release and postsynaptic action of classical neurotransmitters like acetylcholine, norepinephrine, serotonin and dopamine. Galanin co-exists with other neuropeptides, like neuropeptide Y, substance P and vasoactive intestinal peptide, and has been shown to modulate their release and activity. In addition to these actions galanin has more recently been shown to play a trophic and cell survival role to both central and peripheral neurons, implying a role in stroke, brain injury/disease and peripheral neuropathy.

Galanin is a strongly inhibitory, hyperpolarizing peptide, which reduces the excitability of its target cells. Galanin acting at the three galanin receptors opens ATP-sensitive potassium channels, closes calcium channels (N- and L-types), modifies intracellular calcium levels, reduces the stimulatory effect of muscarinic agonists on phospholipase C and modulates the activity of adenylyl cyclase.

Transgenic mice with a disrupted or overexpressing galanin gene have been generated (GalKO, GalOE, respectively). Abnormalities in lactation, pituitary responsiveness to estrogen, and peripheral nerve injury, as well as an increased ability to develop status epilepticus have been described in galanin deficient animals. Animals overexpressing galanin in the central and/or peripheral nervous systems demonstrate suppression of nociception and neuropathic pain behavior, seizure development, a reduction in hippocampal cell death after excitotoxic damage as well as suppressed hippocampal excitability and cognitive deficits.

The diverse physiological effects of galanin are mediated via three G protein-coupled receptors; GalR1-3, which have been cloned from several species (human, rat, mouse), showing only 40-60 % amino acid identity.

GalR1 is localized mainly in the hypothalamus, the hippocampus and the spinal cord, and is negatively coupled to adenylyl cyclase through Gi/Go proteins. GalR2 has been cloned from rat hypothalamus, rat dorsal root ganglia, human placenta, human DNA library and from mouse brain; Unlike GALR1 and GALR3, GALR2 positively couples to phospholipase C mediated via Gq/11 and hence activates the MAP kinase pathways (ERK). It is activated by galanin (2-11), galanin (2-29) and [D-Trp2]-galanin. GalR3 was cloned from rat hypothalamus and is localized mainly in the heart, spleen and testis; it recognizes galanin (2-29) as specific ligand. GalR3 couples to Gi/Go proteins and mediates opening of G protein-coupled inward-rectifying potassium channels (GIRK).

Several peptide type chimeric galanin receptor ligands, M15 (Galantide), M32, M35, M40 and C7, have been synthesized. These can act as galanin receptor antagonists in numerous situations in vivo. Further, these chimeric ligands act often as full or partial agonists in vitro to all three galanin receptors when expressed in various stably transfected cell lines.

Five types of low MW galanin receptor ligands have been reported. A fungal metabolite SCH-202596 (IC50 of 1.7 µM at hGALR1), a series of dithiin-1,1,4,4-tetroxide derivatives that are GalR1 antagonists with submicromolar affinity; galnon, a low molecular weight tripeptidomimetic agonist (Ki of 3-8 mM), which is equally active against all three receptor subtypes and is systemically active and affects appetite, seizures and pain; and galmic, identified from a small synthetic scaffold library with a Ki = 34.2 mM for GalR1. Galmic suppresses long-term potentiation in the dentate gyrus; blocks status epilepticus (i.hc or i.p.); shows antidepressant-like effects in the forced-swim test (i.p.), and it is a potent inhibitor of flinching behavior in the inflammatory pain model induced by formalin injection. Finally, N4-[3-(benzyloxy)phenyl]-2-[4-(2-fluorophenyl)-1-piperazinyl]-N6,N6-dimethyl-4,6-pyrimidinediamine has been reported as a 20 nM GalR3 specific ligand with antidepressant activity.

Galanin-Like Peptide, GALP, a 60 amino acid neuropeptide isolated from porcine hypothalamus. contains the non-variable 1-13 amino acids of galanin between positions 9 and 21. GALP binds GALR1 and GALR2 but neither receptor is thought to mediate the endogenous actions of GALP since the peptide retains biological activity in GALR1 or GALR2 knock-out animals.

The Table below contains accepted modulators and additional information. For a list of additional products, see the Similar Products section below.

Footnotes

* The relevance overlaps between GalR subtypes

Abbreviations

Ach: Acetylcholine
C7: Galanin (1-13)-spantide amide
DA: Dopamine
DRG: Dorsal root ganglion
GALP: Galanin-Like Peptide
GH: Growth hormone
Glu: Glutamate
5-HT: Ser
M15: Galanin (1-13)-substance P (5-11) amide
M32: Galanin (1-13)-neuropeptide Y (25-36) amide
M35: Galanin (1-13)-bradykinin (2-9) amide
M40: Galanin (1-13)-Pro-Pro-Ala-Leu-Ala-Leu-Ala amide
NE: Norepinephrine
SCH-202596: Spirocoumaranon
SP: Substance P

h: human
p: porcine
r: rat Galanin (1-13)-bradykinin (2-9) amide

Similar Products
Loading

References

1.
Bartfai T, Lu X, Badie-Mahdavi H, Barr AM, Mazarati A, Hua X, Yaksh T, Haberhauer G, Ceide SC, Trembleau L, et al. 2004. Galmic, a nonpeptide galanin receptor agonist, affects behaviors in seizure, pain, and forced-swim tests. Proceedings of the National Academy of Sciences. 101(28):10470-10475. http://dx.doi.org/10.1073/pnas.0403802101
2.
Branchek TA, Smith KE, Gerald C, Walker MW. 2000. Galanin receptor subtypes. Trends in Pharmacological Sciences. 21(3):109-117. http://dx.doi.org/10.1016/s0165-6147(00)01446-2
3.
Counts SE. 2003. Galanin in Alzheimer Disease. Molecular Interventions. 3(3):137-156. http://dx.doi.org/10.1124/mi.3.3.137
4.
Elliott-Hunt CR, Marsh B, Bacon A, Pope R, Vanderplank P, Wynick D. 2004. Galanin acts as a neuroprotective factor to the hippocampus. Proceedings of the National Academy of Sciences. 101(14):5105-5110. http://dx.doi.org/10.1073/pnas.0304823101
5.
Fang P, Yu M, Guo L, Bo P, Zhang Z, Shi M. 2012. Galanin and its receptors: A novel strategy for appetite control and obesity therapy. Peptides. 36(2):331-339. http://dx.doi.org/10.1016/j.peptides.2012.05.016
6.
Holmes FE, Mahoney S, King VR, Bacon A, Kerr NCH, Pachnis V, Curtis R, Priestley JV, Wynick D. 2000. Targeted disruption of the galanin gene reduces the number of sensory neurons and their regenerative capacity. Proceedings of the National Academy of Sciences. 97(21):11563-11568. http://dx.doi.org/10.1073/pnas.210221897
7.
Holmes FE, Bacon A, Pope RJP, Vanderplank PA, Kerr NCH, Sukumaran M, Pachnis V, Wynick D. 2003. Transgenic overexpression of galanin in the dorsal root ganglia modulates pain-related behavior. Proceedings of the National Academy of Sciences. 100(10):6180-6185. http://dx.doi.org/10.1073/pnas.0937087100
8.
Kahl, U., et al. 2002. Understanding G-protein-coupled receptors and their role in the CNS, Eds., M.N.Pangalos. Galanin receptors., pp. 286-306. C.H.Davies: Oxford University Press.
9.
Kanazawa T, Misawa K, Carey TE. 2010. Galanin receptor subtypes 1 and 2 as therapeutic targets in head and neck squamous cell carcinoma. Expert Opinion on Therapeutic Targets. 14(3):289-302. http://dx.doi.org/10.1517/14728221003598922
10.
Krasnow SM, Hohmann JG, Gragerov A, Clifton DK, Steiner RA. 2004. Analysis of the Contribution of Galanin Receptors 1 and 2 to the Central Actions of Galanin-Like Peptide. Neuroendocrinology. 79(5):268-277. http://dx.doi.org/10.1159/000079632
11.
Mitsukawa K, Lu X, Bartfai T. 2008. Galanin ? 25 years with a multitalented neuropeptide. Cell. Mol. Life Sci.. 65(12):1796-1805. http://dx.doi.org/10.1007/s00018-008-8153-8
12.
Ogren SO, Kuteeva E, H??kfelt T, Kehr J. 2006. Galanin Receptor Antagonists. CNS Drugs. 20(8):633-654. http://dx.doi.org/10.2165/00023210-200620080-00003
13.
O'Meara G, Coumis U, Ma SY, Kehr J, Mahoney S, Bacon A, Allen SJ, Holmes F, Kahl U, Wang FH, et al. 2000. Galanin regulates the postnatal survival of a subset of basal forebrain cholinergic neurons. Proceedings of the National Academy of Sciences. 97(21):11569-11574. http://dx.doi.org/10.1073/pnas.210254597
14.
Packiarajan M. 2004. 2,4,6-Triaminopyrimidines for the treatment of depression and/or anxiety. [dissertation]. United States Patent Application Publication: Pub. No. 2004/0082587A1, Pub. Date Apr. 29, (2004).
15.
Saar K, Mazarati AM, Mahlapuu R, Hallnemo G, Soomets U, Kilk K, Hellberg S, Pooga M, Tolf B, Shi TS, et al. 2002. Anticonvulsant activity of a nonpeptide galanin receptor agonist. Proceedings of the National Academy of Sciences. 99(10):7136-7141. http://dx.doi.org/10.1073/pnas.102163499
16.
Xu X, Hökfelt T, Bartfai T, Wiesenfeld-Hallin Z. 2000. Galanin and spinal nociceptive mechanisms: recent advances and therapeutic implications. Neuropeptides. 34(3-4):137-147. http://dx.doi.org/10.1054/npep.2000.0820

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.